DRMA
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRMA’s FA Score shows that 1 FA rating(s) are green while.
- DRMA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRMA’s TA Score shows that 5 TA indicator(s) are bullish.
- DRMA’s TA Score: 5 bullish, 2 bearish.
Price Growth
DRMA (@Biotechnology) experienced а +5.88% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.
Reported Earning Dates
DRMA is expected to report earnings on May 11, 2023.
Industries' Descriptions
@Biotechnology (-6.85% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| DRMA | |
| Capitalization | 2.94M |
| EBITDA | -11.53M |
| Gain YTD | 6.667 |
| P/E Ratio | N/A |
| Revenue | 0 |
| Total Cash | 6.14M |
| Total Debt | 175K |
| DRMA | |
|---|---|
| RSI ODDS (%) | N/A |
| Stochastic ODDS (%) | 7 days ago 90% |
| Momentum ODDS (%) | 7 days ago 86% |
| MACD ODDS (%) | 7 days ago 90% |
| TrendWeek ODDS (%) | 7 days ago 90% |
| TrendMonth ODDS (%) | 7 days ago 83% |
| Advances ODDS (%) | 12 days ago 78% |
| Declines ODDS (%) | 7 days ago 90% |
| BollingerBands ODDS (%) | N/A |
| Aroon ODDS (%) | N/A |
DRMA and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with IRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then IRON could also see price increases.
| Ticker / NAME | Correlation To DRMA | 1D Price Change % | ||
|---|---|---|---|---|
| DRMA | 100% | +4.35% | ||
| IRON - DRMA | 43% Loosely correlated | -1.55% | ||
| CDMO - DRMA | 42% Loosely correlated | -0.08% | ||
| KANT - DRMA | 28% Poorly correlated | N/A | ||
| KRRO - DRMA | 28% Poorly correlated | -2.99% | ||
| AVXL - DRMA | 27% Poorly correlated | -0.76% | ||
More | ||||